Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study
Optometry and Vision Science · 2026
DOI: 10.1002/ovs2.70007 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Optometry and Vision Science, 2026. Verfasst von Manon Grégoire und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Strasbourg University Hospital, Strasbourg, France. Hauptthemen laut MEDLINE: Atropine, Eyeglasses, Refraction, Ocular, Myopia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: PHRC.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Myopia control is crucial for pediatric eye care professionals. Although various treatments exist, their comparative efficacy, particularly in European populations, remains unclear. In real‐life conditions, this study aimed to compare different strategies to slow myopia progression.
Methods
This retrospective, nonrandomized study evaluated the efficacy of 0.01%, 0.025%, and 0.05% atropine, defocus incorporated multiple segments/highly aspherical lenslets (DIMS/HAL) spectacles, combined atropine and DIMS/HAL, and single vision spectacles in 288 European children (aged 5–12 years) with myopia progression (≥0.75 D in the past 12 months). Primary outcomes were changes in spherical equivalent refraction (SER) and axial length measured every 6 months for 3 years.
Results
The mean cumulative 3‐year SER progressions were −0.75 ± 0.49, −0.92 ± 0.52, and −1.31 ± 0.75 D for the 0.05%, 0.025%, and 0.01% atropine groups, respectively, −1.31 ± 0.76 D for the DIMS/HAL group, and −1.11 ± 0.65 D for the 0.01% atropine + DIMS/HAL group, showing better myopia progression control compared to those of the control group (−2.14 ± 0.72 D). Atropine exhibited a dose‐dependent effect, with 0.05% atropine achieving the greatest reduction in myopia progression and axial elongation.
Conclusions
This study demonstrates the efficacy of low‐dose atropine and DIMS/HAL spectacles in slowing myopia progression in European children. The 0.05% atropine exhibited the most pronounced myopia control effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Strasbourg University Hospital, Strasbourg, France.
Förderung
- PHRC
Zitieren
APA
Grégoire, M., Dormegny, L., Gaucher, D., Solecki, L., Bourcier, T., & Sauer, A. (2026). Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study. Optometry and Vision Science. https://doi.org/10.1002/ovs2.70007
Vancouver
Grégoire M, Dormegny L, Gaucher D, Solecki L, Bourcier T, Sauer A. Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study. Optometry and Vision Science. 2026. doi:10.1002/ovs2.70007
BibTeX
@article{Grgoire2026,
author = {Grégoire, Manon and Dormegny, Léa and Gaucher, David and Solecki, Lauriana and Bourcier, Tristan and Sauer, Arnaud},
title = {Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study},
journal = {Optometry and Vision Science},
year = {2026},
doi = {10.1002/ovs2.70007}
}
EUVIMED